Background: Recurrent aphthous stomatitis (RAS) poses a considerable challenge within the Otorhinolaryngology domain, impacting patients’ quality of life. Aim and Objectives: This prospective study aimed to assess the efficacy of Rebamipide therapy in managing RAS over 3 months. Methods: A cohort of 60 patients with recurrent aphthous ulcers was enrolled, receiving Rebamipide therapy orally in a Tertiary care center of Central India. Clinical evaluations, pain scores, and ulcer healing rates were recorded at baseline, 1 month, 2 months, and 3 months. Statistical analyses were conducted to assess changes over time. Results: Rebamipide therapy demonstrated a significant reduction in the frequency and severity of aphthous ulcers, with pain scores decreasing progressively over the 3-month period. Ulcer healing rates exhibited a consistent upward trend, reaching substantial levels by the study’s conclusion. Adverse events were minimal, with 5% of patients reported gastrointestinal discomfort. Conclusion: This study contributes evidence supporting Rebamipide as an effective and well-tolerated therapeutic option for RAS. Positive outcomes regarding reduced ulceration, improved pain scores, and enhanced ulcer healing rates underscore its potential clinical utility.

Background: Recurrent aphthous stomatitis (RAS) poses a considerable challenge within the Otorhinolaryngology domain, impacting patients’ quality of life. Aim and Objectives: This prospective study aimed to assess the efficacy of Rebamipide therapy in managing RAS over 3 months. Methods: A cohort of 60 patients with recurrent aphthous ulcers was enrolled, receiving Rebamipide therapy orally in a Tertiary care center of Central India. Clinical evaluations, pain scores, and ulcer healing rates were recorded at baseline, 1 month, 2 months, and 3 months. Statistical analyses were conducted to assess changes over time. Results: Rebamipide therapy demonstrated a significant reduction in the frequency and severity of aphthous ulcers, with pain scores decreasing progressively over the 3-month period. Ulcer healing rates exhibited a consistent upward trend, reaching substantial levels by the study’s conclusion. Adverse events were minimal, with 5% of patients reported gastrointestinal discomfort. Conclusion: This study contributes evidence supporting Rebamipide as an effective and well-tolerated therapeutic option for RAS. Positive outcomes regarding reduced ulceration, improved pain scores, and enhanced ulcer healing rates underscore its potential clinical utility.